Trexquant Investment LP Has $19.98 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Trexquant Investment LP lifted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 36.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 232,246 shares of the company's stock after acquiring an additional 62,267 shares during the quarter. Trexquant Investment LP's holdings in Novo Nordisk A/S were worth $19,978,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Menard Financial Group LLC increased its holdings in shares of Novo Nordisk A/S by 0.8% in the 3rd quarter. Menard Financial Group LLC now owns 12,283 shares of the company's stock valued at $1,463,000 after purchasing an additional 102 shares during the period. Optimist Retirement Group LLC increased its stake in Novo Nordisk A/S by 4.3% in the 3rd quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company's stock valued at $327,000 after buying an additional 112 shares during the period. M. Kulyk & Associates LLC lifted its position in Novo Nordisk A/S by 3.9% in the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after buying an additional 119 shares in the last quarter. Center for Financial Planning Inc. boosted its stake in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares during the period. Finally, Tradewinds Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 2.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after acquiring an additional 124 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Remove Ads

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded up $0.17 on Wednesday, hitting $68.20. The stock had a trading volume of 7,301,268 shares, compared to its average volume of 5,588,217. The company has a market capitalization of $306.05 billion, a price-to-earnings ratio of 20.73, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a twelve month low of $66.57 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm's 50 day moving average price is $81.89 and its 200-day moving average price is $97.68.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is presently 47.72%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Moderate Buy" and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.